Skip to main content

Thomson Reuters, NuMedii Ink Partnership Around Drug Repurposing

Premium

Thomson Reuters and NuMedii this week announced a partnership that will pair NuMedii's underlying informatics technology with curated drug and disease information and systems biology expertise from Thomson Reuters for use in identifying new applications for existing drugs.

Specifically, NuMedii will combine content from Thomson Reuters MetaCore and Integrity repositories with its technology — based on machine learning, pattern matching, and network biology algorithms — and use it to find FDA-approved drugs or discontinued development compounds that are appropriate for repurposing.

"This unique partnership allows NuMedii access to an unparalleled source of knowledge from Thomson Reuters, enabling us to turbo-charge our search and discovery of new applications for existing therapies," according to Gini Deshpande, founder and chief executive officer of NuMedii.

It's also an opportunity to “combine the leading information sources available with novel analytics, data integration, and biomedical expertise in a way that has not been done before outside of a laboratory environment,” Joe Donahue, senior vice president of Thomson Reuters Life Sciences, said in a statement.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.